BR0315579A - Linhagens recombinantes de mva como vacinas potenciais contra malária por p. falciparum - Google Patents

Linhagens recombinantes de mva como vacinas potenciais contra malária por p. falciparum

Info

Publication number
BR0315579A
BR0315579A BR0315579-0A BR0315579A BR0315579A BR 0315579 A BR0315579 A BR 0315579A BR 0315579 A BR0315579 A BR 0315579A BR 0315579 A BR0315579 A BR 0315579A
Authority
BR
Brazil
Prior art keywords
falciparum
recombinant mva
malaria vaccines
mva strains
recombinant viruses
Prior art date
Application number
BR0315579-0A
Other languages
English (en)
Inventor
Gerd Sutter
Hermann Bujard
Nicole Westerfeld
Jun Miao
Original Assignee
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gsf Forschungszentrum Umwelt filed Critical Gsf Forschungszentrum Umwelt
Publication of BR0315579A publication Critical patent/BR0315579A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"LINHAGENS RECOMBINANTES DE MVA COMO VACINAS POTENCIAIS CONTRA MALáRIA POR P. FALCIPARUM". A presente invenção se refere a vírus recombinantes baseados em MVA, os quais compreendem pelo menos um ácido nucléico codificante de uma proteína MSP-1 de Plasmodium falciparum, um fragmento ou uma muteína dela. Além disso, são providos métodos para a produção de vírus recombinantes, vacinas contendo vírus e o uso dos vírus recombinantes na profilaxia e/ou terapia de malária.
BR0315579-0A 2002-10-23 2003-09-26 Linhagens recombinantes de mva como vacinas potenciais contra malária por p. falciparum BR0315579A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002149390 DE10249390A1 (de) 2002-10-23 2002-10-23 Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
PCT/EP2003/010723 WO2004038024A1 (de) 2002-10-23 2003-09-26 Rekombinante mva-stämme als potentielle impfstoffe gegen p. falciparum-malaria

Publications (1)

Publication Number Publication Date
BR0315579A true BR0315579A (pt) 2005-08-30

Family

ID=32102906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315579-0A BR0315579A (pt) 2002-10-23 2003-09-26 Linhagens recombinantes de mva como vacinas potenciais contra malária por p. falciparum

Country Status (10)

Country Link
US (1) US20060127413A1 (pt)
EP (1) EP1554383B1 (pt)
CN (1) CN1708587B (pt)
AT (1) ATE455854T1 (pt)
AU (1) AU2003277909A1 (pt)
BR (1) BR0315579A (pt)
DE (2) DE10249390A1 (pt)
DK (1) DK1554383T3 (pt)
ES (1) ES2339765T3 (pt)
WO (1) WO2004038024A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2431469A3 (en) * 2006-05-15 2012-05-30 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
EP1944313A1 (en) * 2007-01-15 2008-07-16 Vakzine Projekt Management GmbH Recombinant malaria vaccine
EP2141177A1 (en) * 2008-07-04 2010-01-06 Bujard, Hermann MSP-1 protein preparations from Plasmodium
EP2427201B1 (en) 2009-05-05 2015-01-28 Cadila Healthcare Limited Combined measles-malaria vaccine
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
AU2017206102C1 (en) 2016-01-08 2022-02-10 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
US11311612B2 (en) * 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
DE19640817A1 (de) * 1996-10-02 1998-05-14 Hermann Prof Dr Bujard Rekombinantes Herstellungsverfahren für ein vollständiges Malaria-Antigen gp190/MSP 1
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
WO2001085927A1 (en) * 2000-05-08 2001-11-15 Georgetown University Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparum
AU2002343321A1 (en) * 2001-01-26 2003-01-21 Walter Reed Army Institute Of Research Isolation and purification of plasmodium falciparum merozoite protein-142

Also Published As

Publication number Publication date
ATE455854T1 (de) 2010-02-15
DK1554383T3 (da) 2010-05-25
AU2003277909A1 (en) 2004-05-13
DE50312368D1 (de) 2010-03-11
EP1554383A1 (de) 2005-07-20
ES2339765T3 (es) 2010-05-25
WO2004038024A1 (de) 2004-05-06
AU2003277909A8 (en) 2004-05-13
DE10249390A1 (de) 2004-05-13
CN1708587B (zh) 2010-05-05
CN1708587A (zh) 2005-12-14
US20060127413A1 (en) 2006-06-15
EP1554383B1 (de) 2010-01-20

Similar Documents

Publication Publication Date Title
MA52645B1 (fr) Vaccins contre le virus respiratoire
EA201992434A1 (ru) Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия
PH12018501055A1 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
EA200702551A1 (ru) Способ получения эпоксида из хлоргидрина
DE122011100037I1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie.
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
PL1881845T3 (pl) Szczepionki przeciwko wirusowi Nipah
MX359954B (es) Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado.
DE60332355D1 (de) Hla-a24-restringiertes krebsantigenpeptid
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
IN2014DN09351A (pt)
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
CY1118856T1 (el) Εμβολιο pcsk9
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
ATE399210T1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
WO2010037063A3 (en) Plasmodium vaccines, antigens, compositions and methods
BR0315579A (pt) Linhagens recombinantes de mva como vacinas potenciais contra malária por p. falciparum
WO2008048945A3 (en) Conjugates of plasmodium falciparum surface proteins as malaria vaccines
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX2023007319A (es) Vacunas de acido nucleico.
UA85379C2 (ru) Рекомбинантный поксвирус, содержащий как минимум два ati промотора коровьей оспы
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
MX2021013252A (es) Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: GSF-FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GM

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 20140004176/RJ, DE 30/01/2014, E NECESSARIO APRESENTAR O DOCUMENTO DE ALTERACAO COM A DEVIDA LEGALIZACAO CONSULAR.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: GSF-FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GM

Free format text: TENDO EM VISTA QUE A PETICAO NO 20140034264, DE 17/11/2014, ADITADA PELA PETICAO NO 20140036217, DE 10/12/2014, NAO CUMPRE TODAS AS EXIGENCIAS FORMAIS, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO DE ALTERACAO DE NOME, CONFORME ART. 18 DO DECRETO 13.609/43.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: GSF-FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GM

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]